Cancer Genetics, Inc., provider of DNA-based cancer diagnostics, has received a second U.S. patent covering its proprietary FISH-based HPV-Associated Cancer Test (FHACT) for cervical cancer detection in patients. FHACT is designed to assess change across four biomarkers indicating HPV-associated pre-cancers and cancers. It can help prevent unnecessary colposcopies and cervical biopsies, reducing costs and complications associated with these invasive procedures.
On October 21, the United States Patent and Trademark Office granted CGI a product design patent for the test’s four-probe combination. The additional patent granted yesterday, November 11, covers the test’s use on clinical patient samples, including cervical tissue specimen, remnant Pap-smear fluid, or liquid-based cytology. The company believes that receiving patent protection for both the FHACT test design and for its clinical application on patient samples underscores the novelty of the test, and sets a new standard in the field of cervical cancer diagnostics.
“We are pleased to have received a second patent covering our proprietary FHACT test. Having two patents for FHACT further strengthens our position in this important and underserved category, and highlights the test’s ability to revolutionize cervical cancer detection,” says Panna Sharma, CEO of Cancer Genetics, Inc. Learn more about the FHACT test.
Read more
